EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation

Byeong Geun Song iD, Myeongcheol Lee, Danbee Kang, Wonseok Kang, Ju Hyun Shim, Dong Hyun Sinn iD, Geum-Youn Gwak iD

Alimentary Pharmacology & Therapeutics · 2026-10 · 64 (7) · 940-950

DOI: 10.1111/apt.70807 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.06.2026. Verfasst von Byeong Geun Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Korea National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Non‐selective beta blockers (NSBBs) are well established for the prevention of variceal bleeding; however, their potential roles beyond this indication remain a matter of debate. We investigated the clinical outcomes of beta‐blocker use in patients with cirrhosis after hospitalisation for cirrhotic complications, excluding variceal bleeding.

Methods

Using the Korean National Health Insurance Service database, we conducted an emulated target trial among 7725 patients with viral hepatitis‐related cirrhosis hospitalised for hepatic encephalopathy, hepatorenal syndrome, ascites, and/or spontaneous bacterial peritonitis (2013–2023), comparing beta‐blocker users ( n = 2455) and non‐users ( n = 5270). The primary outcome was all‐cause death within 6 months; the secondary outcome was rehospitalisation within 3 months.

Results

Compared to beta‐blocker non‐users, those receiving beta‐blocker therapy had a lower risk of all‐cause death within 6 months [cumulative incidence of mortality 7.8% in beta‐blocker users vs. 11.0% in non‐users; adjusted hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.68–0.97]. A lower risk of all‐cause death associated with beta‐blocker use was observed across complication types and patient subgroups. When analysed by dose and agent, each compared with non‐use, an association with lower mortality was observed for low‐dose beta blockers (HR 0.75, 95% CI 0.59–0.94) and for carvedilol (HR 0.55, 95% CI 0.32–0.94), whereas associations for moderate‐to‐high‐dose therapy (HR 0.90, 95% CI 0.71–1.15) and propranolol (HR 0.87, 95% CI 0.72–1.04) were not statistically significant.

Conclusions

Non‐selective beta blockers were associated with reduced mortality and a modest reduction in all‐cause readmission among patients with viral hepatitis‐related cirrhosis after non‐bleeding decompensating events ( ClinicalTrials.gov : NCT06977685).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsLiver CirrhosisAdultAgedFemaleHumansMaleMiddle AgedHospitalizationRepublic of KoreaTreatment Outcome

Stichwörter der Autor:innen

cirrhosisdecompensationnon‐selective beta‐blockertarget trial emulation

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
  • Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
  • Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Byeong Geun Song, Dong Hyun Sinn, Geum-Youn Gwak

Förderung

  • Korea National Institute of Health

Zitieren

APA

Song, B. G., Lee, M., Kang, D., Kang, W., Shim, J. H., Sinn, D. H., & Gwak, G. Y. (2026). Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Alimentary Pharmacology & Therapeutics, 64(7), 940-950. https://doi.org/10.1111/apt.70807

Vancouver

Song BG, Lee M, Kang D, Kang W, Shim JH, Sinn DH, et al. Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation. Alimentary Pharmacology & Therapeutics. 2026;64(7):940-950. doi:10.1111/apt.70807

BibTeX
@article{Song2026,
  author = {Song, Byeong Geun and Lee, Myeongcheol and Kang, Danbee and Kang, Wonseok and Shim, Ju Hyun and Sinn, Dong Hyun and Gwak, Geum-Youn},
  title = {Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {7},
  pages = {940--950},
  doi = {10.1111/apt.70807}
}
Kostenlos starten →